DocGo (DCGO) AI Stock Analysis

• Market Cap: $151.63M
• Dividend Yield: N/A
• Average Volume (3M): 1.34M
• Price to Earnings (P/E): 12.7
• Beta (1Y): 0.82
• Revenue Growth: -26.00%
• EPS Growth: -103.18%
• Country: US
• Employees: 3,404
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Care Facilities
• EPS (TTM): -0.09
• Shares Outstanding: 99,104,330
• 10 Day Avg. Volume: 627,933
• 30 Day Avg. Volume: 1,339,145
• PEG Ratio: 2.16
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 1.63
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 0.05
• Enterprise Value/Gross Profit: 0.71
• Enterprise Value/Ebitda: 0.63
• 1Y Price Target: $3.11
• Price Target Upside: 94.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 53 Neutral
• Price Target: $1.50 ▼(-6.25%Downside)

DocGo's overall stock score is primarily influenced by a stable financial structure and improving cash flows. However, these positives are offset by significant profitability challenges, a negative P/E ratio, and mixed earnings call sentiment. The absence of strong technical indicators and valuation concerns further weigh on the score.

Positive Factors

Business Expansion

The core payer and care gap closure business is performing well, with significant investments in Artificial Intelligence and automation.

Business Growth

The Transport business is performing well, with revenue increasing due to higher hospital volumes and more trips.

Financial Stability

DocGo has cash and is collecting accounts receivable from the migrant business, which provides a financial runway to ramp up the payer and provider business.

Negative Factors

Earnings

The stock recommendation for DocGo has been downgraded to HOLD due to a disappointing first quarter and a significant downward revision to 2025 guidance.

Government Contracts

The ability to launch new business and timing of RFP decisions have hit a wall due to uncertainty related to federal funding and program cuts.

Revenue Guidance

The slowdown and low visibility in municipal work have led to a significant reduction in revenue guidance for 2025.

DocGo Business Overview & Revenue Model

Company Description

DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; COVID-19 testing; and event services, which include on-site healthcare support at sporting events and concerts. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York.

How the Company Makes Money

DocGo makes money through a diversified revenue model that includes service fees for its mobile health services, telehealth consultations, and medical transportation offerings. The company partners with various healthcare providers, insurance companies, and government entities to deliver its services, often entering into contractual agreements that ensure a steady revenue stream. Key revenue streams include billing for patient visits, charges for transportation services, and fees for telehealth consultations. Additionally, partnerships with healthcare systems and insurers help DocGo expand its reach and customer base, contributing significantly to its earnings.

DocGo Financial Statement Overview

Summary

DocGo presents a stable balance sheet with adequate equity and manageable debt levels. However, the income statement reveals profitability issues and declining revenue, which indicate operational challenges. The cash flow is a bright spot, with improved free cash flow and cash generation, suggesting potential for recovery.

Income Statement

Gross Profit Margin for TTM is 32.58%, while Net Profit Margin is negative at -0.12%, indicating operational challenges. Revenue has decreased from the previous year, showing a negative growth trend. EBIT and EBITDA margins have declined significantly in the TTM period, pointing to reduced profitability.

Balance Sheet

Debt-to-Equity Ratio for TTM is 0.20, showing moderate leverage. Return on Equity is negative at -0.21%, reflecting losses. Equity Ratio is healthy at 71.82%, indicating strong equity financing. Overall, the company maintains a stable financial structure with manageable debt levels.

Cash Flow

Free Cash Flow has grown significantly in the TTM period. Operating Cash Flow to Net Income Ratio is strong, suggesting robust cash generation relative to reported losses. The company has improved its cash flow position, enhancing financial flexibility.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
520.50M	616.56M	624.29M	440.52M	318.72M	94.09M
	Gross Profit
169.62M	197.69M	195.38M	154.72M	109.75M	31.35M
	EBIT
-1.18M	28.69M	15.05M	21.83M	10.49M	-14.76M
	EBITDA
15.34M	45.80M	31.75M	32.40M	28.07M	-9.25M
	Net Income Common Stockholders
-640.62K	19.99M	6.86M	34.58M	23.74M	-14.80M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
89.24M	89.24M	59.29M	157.34M	175.54M	32.42M
	Total Assets
455.62M	455.62M	490.45M	393.28M	309.60M	100.17M
	Total Debt
57.19M	57.19M	46.50M	19.91M	16.51M	13.89M
	Net Debt
-32.05M	-32.05M	-12.79M	-137.42M	-159.03M	-18.53M
	Total Liabilities
140.44M	140.44M	185.28M	114.35M	82.55M	33.23M
	Stockholders Equity
320.92M	320.92M	300.79M	273.23M	219.58M	55.00M
Cash Flow		Free Cash Flow
84.34M	64.50M	-74.35M	23.37M	-8.60M	-16.97M
	Operating Cash Flow
90.63M	70.34M	-64.22M	28.87M	-1.95M	-10.65M
	Investing Cash Flow
-14.91M	-12.72M	-29.88M	-38.45M	-8.59M	-6.04M
	Financing Cash Flow
-31.79M	-24.15M	1.12M	-6.18M	155.21M	-812.09K

DocGo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCGO, the sentiment is Negative. The current price of 1.6 is above the 20-day moving average (MA) of 1.43, below the 50-day MA of 1.95, and below the 200-day MA of 3.39, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 43.54 is Neutral, neither overbought nor oversold. The STOCH value of 86.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCGO.

DocGo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUNA	64 Neutral	$469.98M	11.08	9.93%	―	6.97%	―
TALK	61 Neutral	$550.47M	196.41	2.52%	―	25.02%	―
INNV	54 Neutral	$542.75M	―	-12.03%	―	12.19%	-1.59%
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
DCGO	53 Neutral	$151.63M	12.68	-0.21%	―	-26.00%	-103.18%
CYH	52 Neutral	$456.00M	―	39.18%	―	1.05%	-288.07%
PIII	43 Neutral	$45.64M	―	-131.17%	―	9.79%	-47.01%

DocGo Corporate Events

DocGo Extends Share Repurchase Program to 2025

DocGo Inc. has extended its share repurchase program, initially set to expire on December 31, 2024, to June 30, 2025. The program allows the discretionary repurchase of up to $26 million in common stock, utilizing the company’s existing cash or future cash flows, and may be adjusted or halted without notice depending on various market and corporate conditions.